RxDoctor Payments Data

Gautam Kumar

Cardiovascular Disease · Atlanta, GANPI 1437375391

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,804 of the $28,732 with a category attached, or 65.4%. It is spread thinly across 8 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $17,004 and has fallen 73.5% since, to $4,503 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,732in general payments, 2019–2025

Across 23 payments — averaging $1249.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Osprey Medical Inc$7K
  • Vascular Solutions, Inc.$6K
  • Cordis US CORP.$6K
  • Teleflex LLC$5K
  • Merit Medical Systems Inc$4K
  • Angiodynamics, Inc.$38
  • plus $40 from 2 others
$703,644in research payments, 2019–2025

Across 147 payments — averaging $4786.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$239K
  • Abbott$222K
  • Philips North America LLC$135K
  • M.a. Med Alliance S.A.$49K
  • Gentuity, LLC$25K
  • Penumbra, Inc.$18K
  • plus $16K from 2 others

What the payments were for

  • Consulting fees$18,80465%
  • Speaking & faculty fees$3,50012%
  • Travel & lodging$5,41919%
  • Food & beverage$1,0094%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,732 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$11,913
Medicare patients
29
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate12$146

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →